Compare Stocks: LNAI, ENLV, GNTA, and LTRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$2.11 -3.4%	$7.51	$1.80 ▼ $31.50	$36.27M	1.6	78,455 shs	45,939 shs
GNTA Genenta Science	$1.32 -0.8%	$1.64	$0.55 ▼ $10.00	$31.19M	0.77	1.06 million shs	15,206 shs
LNAI Lunai Bioworks	$2.40 -3.2%	$2.86	$1.21 ▼ $21.20	$10.87M	0.41	1.54 million shs	17,265 shs
LTRN Lantern Pharma	$2.84 +1.4%	$3.44	$1.11 ▼ $5.28	$36.24M	2.34	342,434 shs	12,946 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+3.32%	-2.85%	-71.62%	-81.83%	-89.54%
GNTA Genenta Science	+4.72%	+2.31%	-20.83%	+107.75%	-64.81%
LNAI Lunai Bioworks	-2.75%	+17.54%	-19.74%	-6.91%	+247,999,900.00%
LTRN Lantern Pharma	+1.82%	+11.55%	-28.75%	+37.25%	-46.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$2.11 -3.4%	$7.51	$1.80 ▼ $31.50	$36.27M	1.6	78,455 shs	45,939 shs
GNTA Genenta Science	$1.32 -0.8%	$1.64	$0.55 ▼ $10.00	$31.19M	0.77	1.06 million shs	15,206 shs
LNAI Lunai Bioworks	$2.40 -3.2%	$2.86	$1.21 ▼ $21.20	$10.87M	0.41	1.54 million shs	17,265 shs
LTRN Lantern Pharma	$2.84 +1.4%	$3.44	$1.11 ▼ $5.28	$36.24M	2.34	342,434 shs	12,946 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+3.32%	-2.85%	-71.62%	-81.83%	-89.54%
GNTA Genenta Science	+4.72%	+2.31%	-20.83%	+107.75%	-64.81%
LNAI Lunai Bioworks	-2.75%	+17.54%	-19.74%	-6.91%	+247,999,900.00%
LTRN Lantern Pharma	+1.82%	+11.55%	-28.75%	+37.25%	-46.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	2.50	Moderate Buy	$247.50	11,652.14% Upside
GNTA Genenta Science	1.00	Sell	N/A	N/A
LNAI Lunai Bioworks	1.00	Sell	N/A	N/A
LTRN Lantern Pharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest LNAI, ENLV, GNTA, and LTRN Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/30/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/14/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	LNAI Lunai Bioworks	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/24/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/22/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/7/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.29 per share	N/A
LNAI Lunai Bioworks	N/A	N/A	N/A	N/A	($9.92) per share	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	248.08%	206.39%	8/24/2026 (Estimated)
GNTA Genenta Science	-$7.39M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
LNAI Lunai Bioworks	-$178.01M	-$0.40	N/A	N/A	N/A	N/A	-1,243.45%	-1,617.76%	N/A
LTRN Lantern Pharma	-$17.12M	-$1.45	N/A	N/A	N/A	N/A	-198.34%	-129.08%	8/12/2026 (Estimated)

Latest LNAI, ENLV, GNTA, and LTRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	N/A	GNTA Genenta Science	-$0.2741	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	LTRN Lantern Pharma	-$0.38	N/A	N/A	N/A	N/A	N/A
5/15/2026	Q3 2026	LNAI Lunai Bioworks	N/A	-$0.10	N/A	-$0.10	N/A	$0.02 million
5/15/2026	Q1 2026	LTRN Lantern Pharma	-$0.36	-$0.30	+$0.06	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
LNAI Lunai Bioworks	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	193.24	193.24
GNTA Genenta Science	0.35	14.16	14.16
LNAI Lunai Bioworks	N/A	0.19	0.19
LTRN Lantern Pharma	N/A	1.87	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
GNTA Genenta Science	15.13%
LNAI Lunai Bioworks	71.41%
LTRN Lantern Pharma	28.62%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
GNTA Genenta Science	28.99%
LNAI Lunai Bioworks	0.50%
LTRN Lantern Pharma	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	16.83 million	14.77 million	Optionable
GNTA Genenta Science	7	23.59 million	16.75 million	Not Optionable
LNAI Lunai Bioworks	20	4.53 million	4.51 million	N/A
LTRN Lantern Pharma	20	12.76 million	11.67 million	Optionable

LNAI, ENLV, GNTA, and LTRN Headlines

Recent News About These Companies

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of ...

August 4 at 8:45 AM | finance.yahoo.com

Lantern Pharma Spins Off Open-Medicine AI Platform

August 3 at 6:30 PM | tipranks.com

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

August 3 at 7:30 AM | businesswire.com

Lantern Pharma (NASDAQ:LTRN) Shares Down 3.5% - Here's Why

July 30, 2026 | americanbankingnews.com

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

July 28, 2026 | businesswire.com

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

July 23, 2026 | businesswire.com

Why Lantern Pharma Inc.’s (LTRN) Stock Is Down 5.14%

July 8, 2026 | aaii.comA

Lantern Pharma Launches ZetaOmics™ - an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

July 8, 2026 | tmcnet.com

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

July 8, 2026 | businesswire.com

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

June 2, 2026 | businesswire.com

Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress

June 2, 2026 | tipranks.com

Lantern Pharma (LTRN) Q1 2025 Earnings Transcript

May 21, 2026 | finance.yahoo.com

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

May 19, 2026 | businesswire.com

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026 | businesswire.com

Insider Buying: Lantern Pharma (NASDAQ:LTRN) Director Acquires 48,544 Shares of Stock

May 15, 2026 | insidertrades.com

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 14, 2026 | finance.yahoo.com

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 13, 2026 | businesswire.com

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

May 11, 2026 | businesswire.com

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

April 30, 2026 | seekingalpha.com

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript

April 30, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI, ENLV, GNTA, and LTRN Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$2.12 -0.06 (-2.61%)

As of 11:32 AM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Genenta Science NASDAQ:GNTA

$1.32 -0.01 (-0.75%)

As of 11:30 AM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Lunai Bioworks NASDAQ:LNAI

$2.40 -0.08 (-3.23%)

As of 11:30 AM Eastern

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Lantern Pharma NASDAQ:LTRN

$2.84 +0.04 (+1.43%)

As of 11:28 AM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LNAI, ENLV, GNTA, and LTRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LNAI, ENLV, GNTA, and LTRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LNAI, ENLV, GNTA, and LTRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI, ENLV, GNTA, and LTRN Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

Genenta Science NASDAQ:GNTA

Lunai Bioworks NASDAQ:LNAI

Lantern Pharma NASDAQ:LTRN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LNAI, ENLV, GNTA, and LTRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LNAI, ENLV, GNTA, and LTRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LNAI, ENLV, GNTA, and LTRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI, ENLV, GNTA, and LTRN Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

Genenta Science NASDAQ:GNTA

Lunai Bioworks NASDAQ:LNAI

Lantern Pharma NASDAQ:LTRN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools